Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic

References

• Dona I, Barrionuevo E, Blanca-Lopez N, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014;24:143–153
   PubMed Web of Science ®Google Scholar
• Verma CR, Vasudevan LCB, Pragasan LV. Severe cutaneous adverse drug reactions. Med J Armed Forces India 2013;69:375–383
   PubMedGoogle Scholar
• Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013;65:779–808
   PubMed Web of Science ®Google Scholar
• Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307–317
   PubMed Web of Science ®Google Scholar
• Merk HF, Arzneimittelreaktionen. In: Saloga J, Klimek L, Buhl R, et al, eds. Allergologie-Handbuch. 2. Aufl. Stuttgart: Schattauer; 2012:426–439
   Google Scholar
• Sharma AM, Novalen M, Tanino T, Uetrecht J. 12-OH-Nevirapine sulfate, formed in the skin, is responsible for Nevirapine-induced skin rash. Chem Res Toxicol 2013;26:817–827
   PubMed Web of Science ®Google Scholar
• Pauluhn J. Development of a respiratory sensitization/elicitation protocol of toluene diisocyanate (TDI) in Brown Norway rats to derive an elicitation-based occupational exposure level. Toxicology 2014;319:10–22
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J 2005;7:E834–E846
   PubMed Web of Science ®Google Scholar
• Cho T, Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol 2017;30:295–314
   PubMed Web of Science ®Google Scholar
• Modi BG, Neustadter J, Binda E, et al. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012;335:104–108
   PubMed Web of Science ®Google Scholar
• Monteiro D, Egipto P, Barbosa J, et al. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). Cutan Ocul Toxicol 2017;36:163–168
   PubMed Web of Science ®Google Scholar
• Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007;39:659–698
   PubMed Web of Science ®Google Scholar
• Svensson CK. Biotransformation of drugs in human skin. Drug Metab Dispos 2009;37:247–253
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014;312:525–534
   PubMed Web of Science ®Google Scholar
• Merk HF, Baron JM, Neis MM, et al. Skin: major target organ of allergic reactions to small molecular weight compounds. Toxicol Appl Pharmacol 2007;224:313–317
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Adam J, Watkins S, et al. Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immunol 2015;168:13–24
   PubMed Web of Science ®Google Scholar
• Bharadwaj M, Illing P, Theodossis A, et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012;52:401–431
   PubMed Web of Science ®Google Scholar
• Rive CM, Bourke J, Philipps EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev 2013;34:15–38
   PubMedGoogle Scholar
• Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011;128:1266–1276
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen JK, Ko TM, et al. Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. J Allergy Clin Immunol 2015;135:1063–1065
   PubMed Web of Science ®Google Scholar
• Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013;43:1246–1255
   PubMed Web of Science ®Google Scholar
• Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol 2014;192:2984–2993
   PubMed Web of Science ®Google Scholar
• Sullivan A, Gibson A, Park BK, Naisbitt DJ. Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? Expert Opin Drug Metab Toxicol 2015;11:357–368
   PubMed Web of Science ®Google Scholar
• Roychowdhury S, Vyas PM, Reilly TP, et al. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 2005;314:43–52
   PubMed Web of Science ®Google Scholar
• Hertl M, Jugert F, Merk HF. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995;132:215–220
   PubMed Web of Science ®Google Scholar
• Blanca-López N, Ariza A, Doňa I, et al. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy 2013;43:560–567
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Aspirin-exacerbated cutaneous disease. Immunol Allergy Clin N Am 2013;33:251–262
   PubMed Web of Science ®Google Scholar
• Steinke JW, Platts-Mills TAE, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 2015;135:589–596
   PubMed Web of Science ®Google Scholar
• Kim SH, Sanak M, Park HS. Genetics of hypersensitivity to Aspirin and nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2013;33:177–194
   PubMed Web of Science ®Google Scholar
• McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237–241
   PubMed Web of Science ®Google Scholar
• Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995;105:95S–98S
   PubMed Web of Science ®Google Scholar
• Hertl M, Bohlen H, Jugert F, et al. Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics. J Invest Dermatol 1993;101:794–799
   PubMed Web of Science ®Google Scholar
• Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009;9:316–321
   PubMed Web of Science ®Google Scholar
• Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013;168:726–732
   PubMed Web of Science ®Google Scholar
• Saito N, Yoshioka N, Abe R, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. J Allergy Clin Immunol 2013;131:434–441e9
   PubMed Web of Science ®Google Scholar
• Feoktistova M, Leverkus M. Programmed necrosis and necroptosis signalling. FEBS J 2015;282:19–31
   PubMed Web of Science ®Google Scholar
• Ukida A, Aoyama Y, Shirafuji Y, et al. Steroid treatment during the acute stage of severe drug eruptions is associated with improved long-term outcomes in the generation of autoantibodies: Longitudinal analysis up to 12 years of autoantibodies against epidermal proteins. J invest Dermatol 2013;133(Suppl. 1):S1–S311
   PubMed Web of Science ®Google Scholar
• Saito N, Qiao H, Yanagi T, et al. A novel necroptosis pathway of annexin A1/ FPR1 interaction in severe cutaneous adverse drug reactions. J invest Dermatol 2013;133(Suppl. 1):S1–S311
   PubMed Web of Science ®Google Scholar
• Hotzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016;38:75–86
   PubMed Web of Science ®Google Scholar
• Husain Z, Reddy BY, Schwartz RA. DRESS syndrome (Part I. Clinical perspectives). J Am Acad Dermatol 2013;68:693.e1–693.e14
   Web of Science ®Google Scholar
• Viard-Leveugle I, Gaide O, Jankovic D, et al. TNF-α and IFN-γ are potential inducers of fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013;133:489–498
   PubMed Web of Science ®Google Scholar
• Takeda Y, Tsujino K, Kijima T, Kumanogoh A. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Pref Adherence 2014;8:361–370
   PubMed Web of Science ®Google Scholar
• Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013;133:1904–1907
   PubMed Web of Science ®Google Scholar
• Elkeeb D, Elkeeb L, Maibach H. Photosensitivity: a current biological overview. Cutan Ocul Toxicol 2012;31:263–272
   PubMed Web of Science ®Google Scholar
• Neumann NJ, Schauder S. Phototoxische Und Photoallergische Reaktionen. Hautarzt 2013;64:354–362
   PubMed Web of Science ®Google Scholar
• Waton J, Tréchot P, Loss-Ayav C, et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. BJD 2009;160:786–794
   Web of Science ®Google Scholar
• Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2016;71:1103–1134
   PubMed Web of Science ®Google Scholar
• Martin M, Wurpts G, Ott H, et al. In vitro detection and characterization of drug hypersensitivity using flow cytometry. Allergy 2010;65:32–39
   PubMed Web of Science ®Google Scholar
• Martin M, Ott H, Merk HF, Sachs B. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins. Br J Dermatol 2011;164:68–75
   PubMed Web of Science ®Google Scholar
• Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. Br J Dermatol 2013;168:539–549
   PubMed Web of Science ®Google Scholar
• Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T cell-mediated drug allergy. Clin Exp Allergy 2011;41:461–470
   PubMed Web of Science ®Google Scholar
• Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702–712
   PubMed Web of Science ®Google Scholar
• De Weck AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. J Investig Allergol Clin Immunol 2009;19:91–110
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Virgili G, Gaeta F, Romano A, et al. High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics. PLOS One 2015;10:e0121857
   PubMed Web of Science ®Google Scholar
• Lafuente A, Javaloyes G, Berroa F, et al. Early skin testing is effective for diagnosis of hypersensitivity reactions occurring during anesthesia. Allergy 2013;68:820–822
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhou J. Toxic epidermal necrolysis: 13 years of experience in the management at a Department of Dermatology in China. Cutan Ocul Toxicol 2017;36:19–24
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature 2010;11:700–714
   Web of Science ®Google Scholar
• Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009;182:8071–8079
   PubMed Web of Science ®Google Scholar
• Prieto-Garcia A, Tomás M, Pineda R, et al. Skin test-positive immediate hypersensitivity reaction to iodinated contrast media: the role of controlled challenge testing. J Investig Allergol Clin Immunol 2013;23:183–189
   PubMed Web of Science ®Google Scholar
• Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 2015;3:175–185
   PubMed Web of Science ®Google Scholar
• Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by Immune Checkpoint inhibitor therapy. Front Pharmacol 2017;8:1–14
   PubMed Web of Science ®Google Scholar
• Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672–683
   PubMed Web of Science ®Google Scholar
• Balci DD, Peker E, Duram N, Dogramaci CA. Sulfasalazine-induced hypersensitivity syndrome in a 15 years old boy associated with human herpesvirus-6 reactivation. Cutan Ocul Toxicol 2009;28:45–47
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–153
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang CY, Cho YT, et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013;68:459–465
   PubMed Web of Science ®Google Scholar
• Hertl M, Geisel J, Boecker C, Merk HF. Selective generation of CD8+ T-cell clones from the peripheral blood of patients with cutaneous reactions to beta-lactam antibiotics. Br J Dermatol 1993;128:619–626
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013;133:2514–2521
   PubMed Web of Science ®Google Scholar
• Torres MJ, Gomez F, Doňa I, et al. Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. Allergy 2012;67:929–935
   PubMed Web of Science ®Google Scholar
• Venturini DM, Lobera LT, del Pozo Gil MD, et al. In vivo diagnostic tests in adverse reactions to quinolones. J Investig Allergol Clin Immunol 2007;17:393–398
   PubMed Web of Science ®Google Scholar
• Walsh S, Diaz-Cano S, Higgins E, et al. Drug reactions with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 2013;168:391–401
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: Pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011;127:60–66
   PubMed Web of Science ®Google Scholar
• Brož P, Harr T, Hecking C, et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy 2012;67:647–652
   PubMed Web of Science ®Google Scholar